Article

Hyalinizing trabecular tumors of the thyroid gland are almost all benign.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
The American journal of surgical pathology (Impact Factor: 4.59). 10/2008; 32(12):1877-89. DOI: 10.1097/PAS.0b013e31817a8f1b
Source: PubMed

ABSTRACT In 1987, Carney et al reported 11 thyroid tumors with the following features: circumscription or encapsulation, trabecular architecture with intratrabecular hyalin and colloid, polygonal and spindle cells, nuclei with frequent grooves and cytoplasmic inclusions, occasional psammoma bodies, and a low mitotic rate. The neoplasms did not recur or metastasize during a follow-up period that averaged 10 years, and they were titled hyalinizing trabecular adenomas. Subsequently, the nuclear features of the neoplasm led to the introduction of 2 modified titles for it, hyalinizing trabecular tumor and hyalinizing trabecular neoplasm. Later, discovery of RET/PTC mutations in the tumor resulted in it being designated as a type of papillary thyroid carcinoma. We studied 119 neoplasms of the type outlined, collected over a 20-year period, for invasion, recurrence and metastasis, and obtained follow-up in 96% of the cases. One hundred eighteen tumors showed no evidence of aggressive behavior (capsular, vascular, and parenchymal invasion), local recurrence, or metastasis. One tumor showed vascular and capsular invasion, and pulmonary metastasis. We conclude that the overwhelming majority of hyalinizing trabecular tumors of the thyroid behave as benign neoplasms and that, at this time, hyalinizing trabecular adenoma is the most appropriate title for them.

0 Bookmarks
 · 
135 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hyalinizing trabecular tumors (HTT) are very rare thyroid tumors whose diagnosis is difficult, particularly in cytology. They are frequently diagnosed as papillary carcinomas due to the cytological similarities between those two tumors (anisocariosis, intranuclear cytoplasmic inclusions, nuclear grooves and nuclear overlapping). Here, we report two HTT cases which were initially diagnosed as papillary carcinoma, on the preoperative cytology and for which the patients underwent total thyroidectomy with lymph node dissection. From these two cases and a literature review, we have searched for diagnostic criteria which could increase the sensitivity of HTT diagnosis in thin layer cytology. We have found that only the identification of the fibrillar and hyaline material within the cellular cluster of the HTT seems discriminating between both tumors, even though it is difficult to diagnose it is difficult to diagnose on thin layer cytology. One major help for the diagnosis would be the typical membranous and cytoplasmic MIB-1 immunostaining. However, no experiment has been undertaken with thin layer smears for HTT.
    Annales de Pathologie 08/2011; 31(4):307-311. · 0.29 Impact Factor
  • Value in Health 11/2005; 8(6). · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background/Aims: Hyalinizing trabecular tumors are rare neoplasms of the thyroid gland often mistaken for thyroid carcinoma on fine-needle aspiration. We review the distinguishing characteristics of hyalinizing trabecular tumors and their management. Methods: We present the case of a patient diagnosed with papillary thyroid carcinoma on fine-needle aspiration as well as a review of the literature. Results: Intraoperative findings were felt to be inconsistent with papillary thyroid carcinoma and only a thyroid lobectomy was performed pending the results from pathologic evaluation, which confirmed a benign process and a diagnosis of hyalinizing trabecular tumor. Due to the diagnostic difficulty in distinguishing hyalinizing trabecular tumors from thyroid carcinomas on fine-needle aspiration, many patients receive overtreatment for what is primarily a benign disease. Conclusions: Recognition of hyalinizing trabecular tumors as a possible benign etiology of a thyroid mass can facilitate appropriate management. © 2013 S. Karger AG, Basel.
    ORL 10/2013; 75(6):309-313. · 1.10 Impact Factor